4th Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. S. 1895, No Surprises Act. S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 CARES Act Implementation and H.R. 266, Paycheck Protection Program and Health Care Enhancement Act and COVID supply chain issues H.R. 133, Consolidated Appropriations Act, 2021.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States; Food & Drug Administration (FDA)

Bills named: H.R. 266 (116th), H.R. 133 (116th), H.R. 3 (116th), S. 2543 (116th), S. 1895 (116th), H.R. 6201 (116th)

Medicare/Medicaid MMM

Healthcare transparency, costs and access to affordable medication and other healthcare items and services. S. 178, HEALS Act.

LobbyistCovered position, as disclosed
DEAN ROSEN —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; White House Office

Bills named: S. 178 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.